HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, TR-06800 Ankara, Turkey
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2019年 / 175卷 / 01期
关键词：
D O I：
10.1007/s10549-019-05151-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 261
页数：1
相关论文
共 50 条
  • [21] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
  • [22] Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-positive breast cancer patients
    Sato, A.
    Maeda, Y.
    Matsumoto, A.
    Ikeda, T.
    Jinno, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1409 - S1409
  • [23] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Hou, Yanjun
    Nitta, Hiroaki
    Wei, Lai
    Banks, Peter M.
    Portier, Bryce
    Parwani, Anil V.
    Li, Zaibo
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 447 - 457
  • [24] Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+breast cancer
    Branco, Francisco P.
    Machado, Duarte
    Silva, Filipa F.
    Andre, Saudade
    Catarino, Ana
    Madureira, Rosa
    Pinto, Joao M.
    Godinho, Joao P.
    Simoes, Pedro D.
    Brito, Margarida
    Casa-Nova, Mafalda
    Moreira, Antbnio R.
    Passos-Coelho, Jose L.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 6110 - 6116
  • [25] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
    Guarneri, V.
    Dieci, M. V.
    Barbieri, E.
    Piacentini, F.
    Omarini, C.
    Ficarra, G.
    Bettelli, S.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
  • [26] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Yanjun Hou
    Hiroaki Nitta
    Lai Wei
    Peter M. Banks
    Bryce Portier
    Anil V. Parwani
    Zaibo Li
    Breast Cancer Research and Treatment, 2017, 166 : 447 - 457
  • [27] In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
    Lien, Huang-Chun
    Lo, Chiao
    Lee, Yi-Hsuang
    Lin, Po-Hang
    Wang, Ming-Yang
    Kuo, Wen-Hung
    Tsai, Li-Wei
    Lu, Yen-Shen
    Hu, Hsiang-Wei
    Li, Yu-Chia
    Huang, Chiun-Sheng
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [28] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [29] Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment
    Abduyev, Zohrab
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2208 - 2208
  • [30] Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns
    Lv, Hong
    Bai, Qian-Ming
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    CANCER RESEARCH, 2022, 82 (04)
12345